ClinicalTrials.gg
CompletedNCT03245736Updated Nov 4, 2021Results posted

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

A Phase 2 interventional study of Tisotumab Vedotin in Ovary Cancer, Cervix Cancer and Endometrium Cancer, sponsored by Seagen Inc.. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-04.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Ovarian Neoplasms by Pfizer — 1 open to participants now, 4 under way, 1 of them phase 3. Ovarian Neoplasms · Pfizer.

Enrollment
36th of 38
5 · median 52
Started
2017
the only one that year
Phase 2
7 of 38
none open now
Registered
13th of 38
by date

Among the 38 studies in Ovarian Neoplasms by Pfizer, this one is the 36th largest by enrollment, is the only one that started in 2017, is one of 7 in phase 2, and was the 13th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

1 of the 38 studies in Ovarian Neoplasms by Pfizer is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Ovarian Neoplasms by Pfizer, or all of them as a file.
02

Study summary

The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.

Read the detailed description

This is an open-label, multicenter trial to collect long-term safety and efficacy data and to provide ongoing access to tisotumab vedotin for patients with solid tumors who have completed a tisotumab vedotin base trial.

03

Conditions studied

  • Ovary Cancer
  • Cervix Cancer
  • Endometrium Cancer
  • Bladder Cancer
  • Prostate Cancer
  • Esophagus Cancer
  • Lung Cancer, Nonsmall Cell
  • Squamous Cell Carcinoma of the Head and Neck
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have either:

    1. completed the base trial and have shown a clinical benefit of SD or better and have never met any withdrawal criteria as defined in the tisotumab vedotin base protocol, or
    2. not completed treatment as defined in the base protocol for reasons that are not considered critical and unmanageable for the safety of the patient (as evaluated by the investigator and/or the sponsor) and the patient clearly showed response of PR or better.
  • Patients must not have experienced radiographic disease progression or clinical signs of symptoms of instability requiring urgent intervention.
  • Patients must not have received any other anti-cancer treatment (including surgery, radiation or systemic chemotherapy) since the base trial.
  • Acceptable renal function
  • Acceptable liver function
  • Acceptable hematological status
  • (ECOG) performance status of 0 or 1.
  • A negative serum pregnancy test (if female and aged between 18-55 years old).
  • Patients, both females and males, of must agree to use adequate during and for six months after the last infusion of tisotumab vedotin.

    1. Adequate contraception for women is defined as hormonal birth control or an intrauterine device (safe hormonal contraceptives include contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release). In countries where two highly effective methods of contraception are required this will be an inclusion criterion.
    2. Male patients must be willing to use a latex condom during any sexual contact with females of during and for six months after the last infusion of tisotumab vedotin, even after having undergone a successful vasectomy.
    3. In order to be considered as sterilized or infertile, a patient must have undergone surgical sterilization (vasectomy/bilateral tubectomy; hysterectomy and bilateral ovariectomy) or be (12 months or more with no period prior to enrolment).
  • Following receipt of verbal and written information about the trial, patients must provide signed before any trial-related activity is carried out.
  • Acceptable coagulation status as defined in the applicable base protocol

    1. GEN701: Acceptable coagulation status: (INR) ≤ 1.2 (without anticoagulant therapy), and activated partial thromboplastin time (aPTT) ≤ 1.25 ; patients on stable doses of therapeutic anti-coagulative treatment for ≥ 8 weeks (e.g., warfarin) must have an INR \< 3.
    2. GEN702: Acceptable coagulation status defined as: INR ≤ 1.2 (without anticoagulant therapy), and aPTT ≤ ULN.

Exclusion criteria

Exclusion Criteria:

  • Presence of (Common Terminology Criteria for Adverse Events) grade ≥ 2 peripheral neuropathy.
  • active viral, bacterial or fungal infection requiring:

    1. Intravenous treatment with anti-infective therapy that has been administered less than two weeks prior to first dose in this trial, or
    2. Oral treatment with anti-infective therapy that has been administered less than one week prior to first dose in this trial.
    3. Prophylactic anti-infective therapy, which is given without clinical symptoms is allowed.
  • Ongoing acute or chronic inflammatory skin disease.
  • Women who are breast feeding.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Tisotumab Vedotin

    All patients will be administered tisotumab vedotin (HuMax-TF-ADC) in 21 day treatment cycles.

    Drug: Tisotumab Vedotin

Interventions

  • All patients in the trial will be administered tisotumab vedotin (HuMax-TF-ADC).

    Also known as: TIVDAK

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE)

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment emergent adverse event (TEAE) is an AE occurring on or after the first dose of study medication or worsening during treatment period.

    Time frame: Day 1 to Week 24 plus 30 days

Secondary outcomes

  1. Objective Response Rate

    Objective Response was investigator-assessed based on the Response Evaluation Criteria In Solid Tumors version 1.1 \[RECIST 1.1\] criteria. The best overall response was reported for each participant.

    Time frame: Day 1 to Week 24 plus 30 days

  2. Number of Participants With Increased Cancer Antigen (CA 125) Levels

    The number of participants with ovarian cancer whose levels of CA125 Antigen had increased since the end of the base trial are presented.

    Time frame: Day 1 to Week 24 plus 30 days

  3. Number of Participants With Increased Prostate Specific Antigen (PSA)

    The number of participants with prostate cancer whose levels of PSA had increased since the end of the base trial are presented.

    Time frame: Day 1 to Week 24 plus 30 days

07

Results

Posted Nov 4, 2021

Participant flow

All participants entered the trial following completion of other tisotumab vedotin trials such as GEN701 and GEN702. A total of 5 participants took part in the trial at 3 sites in the United Kingdom and 1 site in the United States from 23 August 2017 to 10 January 2019.

Participant flow — Overall Study
MilestoneTisotumab Vedotin
Started5
Completed0
Not completed5
Withdrew: Adverse event1
Withdrew: Progressive disease4

Outcome measures

PrimaryNumber of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE)

An adverse event (AE) is any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment emergent adverse event (TEAE) is an AE occurring on or after the first dose of study medication or worsening during treatment period.

Time frame:
Day 1 to Week 24 plus 30 days
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE)
ParticipantsTisotumab Vedotin
Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE)5
SecondaryObjective Response Rate

Objective Response was investigator-assessed based on the Response Evaluation Criteria In Solid Tumors version 1.1 \[RECIST 1.1\] criteria. The best overall response was reported for each participant.

Time frame:
Day 1 to Week 24 plus 30 days
Reported as:
Count of participants · Participants
Objective Response Rate
ParticipantsTisotumab Vedotin
Complete Response0
Partial Response2
Stable Disease2
Progressive Disease1
SecondaryNumber of Participants With Increased Cancer Antigen (CA 125) Levels

The number of participants with ovarian cancer whose levels of CA125 Antigen had increased since the end of the base trial are presented.

Time frame:
Day 1 to Week 24 plus 30 days
Reported as:
Count of participants · Participants
Number of Participants With Increased Cancer Antigen (CA 125) Levels
ParticipantsTisotumab Vedotin
Number of Participants With Increased Cancer Antigen (CA 125) Levels1
SecondaryNumber of Participants With Increased Prostate Specific Antigen (PSA)

The number of participants with prostate cancer whose levels of PSA had increased since the end of the base trial are presented.

Time frame:
Day 1 to Week 24 plus 30 days

No measurements were reported for this outcome.

Adverse events

Collected over Day 1 to Week 24 plus 30 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Overall0/5 (0%)1/5 (20%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventOverall
Peripheral sensorimotor neuropathyNervous system disorders1/5
Most frequent other events
Showing 10 of 15
Most frequent other events
EventOverall
Neuropathy peripheralNervous system disorders4/5
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/5
Decreased appetiteMetabolism and nutrition disorders2/5
Balance disorderNervous system disorders1/5
Retinal exudatesEye disorders1/5
ArthralgiaMusculoskeletal and connective tissue disorders1/5
Localised infectionInfections and infestations1/5
FatigueGeneral disorders1/5
Ocular toxicityEye disorders1/5
Corneal thinningEye disorders1/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)Tisotumab Vedotin
Geometric mean50.4 ± 10.46
Age, Customized
Age, Customized(Participants)Tisotumab Vedotin
In utero0
Preterm newborn infants (gestational age < 37 wks)0
Newborns (0-27 days)0
Infants and toddlers (28 days-23 months)0
Children (2-11 years)0
Adolescents (12-17 years)0
Adults (18-64 years)5
From 65-84 years0
85 years and over0
Sex: Female, Male
Sex: Female, Male(Participants)Tisotumab Vedotin
Female5
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tisotumab Vedotin
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White5
More than one race0
Unknown or Not Reported0
08

Study locations

4 sites
  • Brian Slomovitz
    Miami, Florida 33136, United States
  • Johann de Bono
    Chelsea, SM2 5PT, United Kingdom
  • Beatson Cancer Centre
    Glasgow, United Kingdom
  • Fiona Thistlethwaite
    Manchester, M20 4BX, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Jan 2019, 16 months.

Results were first posted in Nov 2021, 2 years 9 months after primary completion. A results delay was requested in Jan 2020.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 16 months is below that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2017
First posted
Aug 10, 2017
StartActual
Aug 23, 2017
Primary completionActual
Jan 10, 2019
CompletionActual
Jan 10, 2019
Results delay requested
Jan 14, 2020
Results first posted
Nov 4, 2021
Last update
Nov 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03245736
Lead sponsor
Seagen Inc.
Collaborators
Genmab
Responsible party
Sponsor
First posted
Aug 10, 2017
Start date
Aug 23, 2017
Primary completion
Jan 10, 2019
Completion
Jan 10, 2019
Results posted
Nov 4, 2021
Last update
Nov 4, 2021

Study contacts

Medical Director
study director · Genmab

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tisotumab vedotin

Start the discussion